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ABSTRACT
Background. The influence of morphological status on
the long-term outcome of patients undergoing liver resec-
tion for intrahepatic cholangiocarcinoma (ICC) is poorly
defined. We sought to study the impact of morphological
status on overall survival (OS) of patients undergoing
curative-intent resection for ICC.
Methods. A total of 1083 patients who underwent liver
resection for ICC between 1990 and 2015 were identified.
Data on clinicopathological characteristics, operative
details, and morphological status were recorded and ana-
lyzed. A propensity score-matched analysis was performed
to reduce confounding biases.
Results. Among 1083 patients, 941(86.9%) had a mass-
forming (MF) or intraductal-growth (IG) type, while 142
(13.1%) had a periductal-infiltrating (PI) or MF with PI
components (MF ? PI) ICC. Patients with an MF/IG ICC
had a 5-year OS of 41.8% (95% confidence interval [CI]
37.7–45.9) compared with 25.5% (95% CI 17.3–34.4) for
patients with a PI/MF ? PI (p\ 0.001). Morphological
type was found to be an independent predictor of OS as
patients with a PI/MF ? PI ICC had a higher hazard of
death (hazard ratio [HR] 1.42, 95% CI 1.11–1.82;
p = 0.006) compared with patients who had an MF/IG
ICC. Compared with T1a–T1b–T2 MF/IG tumors, T1a–
T1b–T2 PI/MF ? PI and T3–T4 PI/MF ? PI tumors were
associated with an increased risk of death (HR 1.47 vs.
3.59). Conversely, patients with T3–T4 MF/IG tumors had
a similar risk of death compared with T1a–T1b–T2 MF/IG
patients (p = 0.95).
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Conclusion. Among patients undergoing curative-intent
resection of ICC, morphological status was a predictor of
long-term outcome. Patients with PI or MF ? PI ICC had
an approximately 45% increased risk of death long-term
compared with patients who had an MF or IG ICC.
Intrahepatic cholangiocarcinoma (ICC) is a primary liver
tumor that originates from the endothelial cells of segmental
or proximal branches of the bile duct.1 It accounts for
10–15% of all primary liver malignancies and its incidence
and mortality are increasing worldwide.2 Surgical resection
remains the cornerstone of potentially curative therapy,
however 5-year survival after curative-intent resection
remains only 25–30%.2–11 Several studies have identified
clinicopathological factors associated with long-term out-
comes.2,7,9,12–18 Specifically, preoperative cancer antigen
(CA) 19–9 levels, tumor number and size, lymph node status,
margin status, and vascular invasion have each been asso-
ciated with an increased risk of death long-term.2,7,9,12–17,19
Another less-considered clinicopathological character-
istic of ICC involves tumor morphology. The Liver Cancer
Study Group of Japan has classified ICC into several cate-
gories based on gross appearance: mass-forming (MF) type,
periductal-infiltrating (PI) type, and intraductal-growth (IG)
type. The MF type is characterized by a defined mass within
the liver parenchyma, while the PI subtype extends longi-
tudinally along the bile duct, often with enhancement of the
bile duct. In contrast, the IG type grows toward or within the
lumen of the bile duct.20 While these different ICC mor-
phologies have been defined, few studies have investigated
the impact of tumor morphology on long-term prognosis
following resection of ICC.21–23 Shimada et al. reported that
MF ? PI ICC had a higher incidence of positive surgical
margins, as well as a higher risk of local recurrence.21
However, previous studies have been limited due to small
patient cohorts derived from single institutions.
Given the lack of data, the objective of the current study
was to define the impact of ICC morphologic status relative
to long-term outcomes following liver resection for ICC
using a large multi-institutional international cohort. In
addition, we sought to define the relationship of tumor
morphology and the American Joint Committee on Cancer
(AJCC) 8th edition T categories.
INTRODUCTION
PATIENTS AND METHODS
Study Population and Data Collection
Patients who underwent hepatic resection for histologi-
cally confirmed ICC at one of 14 major hepatobiliary
centers between 1990 and 2015 were identified. The 14
medical centers included Johns Hopkins Hospital, Balti-
more, MD, USA; Stanford University, Stanford, CA, USA;
University of Virginia, Charlottesville, VA, USA; Emory
University, Atlanta, GA, USA; Fundeni Clinical Institute
of Digestive Disease, Bucharest, Romania; Curry Cabral
Hospital, Lisbon, Portugal; Ospedale San Raffaele, Milan,
Italy; Royal Prince Alfred Hospital, University of Sydney,
Sydney, NSW, Australia; Eastern Hepatobiliary Surgery
Hospital, Shanghai, China; Beaujon Hospital, Clichy,
France; University of Ottawa, Ottawa, ON, Canada; Eras-
mus University Medical Centre, Rotterdam, The
Netherlands; Yokohama City University School of Medi-
cine, Yokohama, Japan; and University of Verona, School
of Medicine, Verona, Italy. The Institutional Review Board
of the participating institutions approved the study. Only
patients who underwent curative-intent liver resection for
nonmetastatic tumors were included. Patients who under-
went a noncurative resection (R2), as well as patients who
received only ablation or intra-arterial therapy, were
excluded.
Standard patient demographic and clinicopathological
characteristics were collected, including age, sex, Ameri-
can Society of Anesthesiologists (ASA) class, presence of
cirrhosis in the underlying liver, and serum level of car-
cinoembryonic antigen (CEA) and CA19-9. ICC-specific
characteristics, including tumor location, tumor burden,
invasion of adjacent organs, liver capsule involvement,
margin status, tumor grade, major vascular/lymphovascu-
lar/perineural invasion, and nodal status were collected.
For the purposes of analyses, patients were grouped as MF/
IG type versus PI/MF with PI components (MF ? PI) ICC.
For all cases, the imaging and pathological data were
reviewed to determine the macroscopic morphologic sub-
type. In addition, since early 2000, ICC morphological type
has been included in the pathological report as a standard
data field regarding tumor characteristics at the 14 partic-
ipating centers. Treatment-related data such as type and
extent of hepatic resection, lymphadenectomy, and receipt
of neoadjuvant chemotherapy were also recorded. Tumor
stage was categorized according to the 8th edition of the
AJCC.24 The presence of multifocal ICC, invasion of
adjacent organs, liver capsule involvement, margin status,
tumor grade, vascular/lymphovascular/perineural invasion,
nodal status, morphological type, and AJCC stage were
determined based on final pathological reports.
Statistical Analysis
Discrete variables were described as medians with
interquartile range (IQR) and categorical variables were
recorded as totals and frequencies. Univariable compar-
isons were assessed using the Chi square test or Fisher’s
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exact test as appropriate. Univariable and multivariable
analyses were performed using Cox proportional hazard
regression models to assess possible associations among
covariates. Variables significant on univariable analysis
(p\ 0.05) were entered into the multivariable model and
backward selection was used to eliminate nonsignificant
variables at p\ 0.10. Furthermore, to account for any
potential residual confounders in the effect of morphologic
subtype classification on survival, propensity scores were
estimated using a logistic regression model, with mor-
phological type specified as MF/IG versus PI/MF ? PI.
Age, ASA score, underlying liver disease, neoadjuvant
chemotherapy, type of surgery, margin status, liver capsule
involvement, invasion of adjacent organs, tumor size and
number, tumor differentiation, major vascular invasion,
lymphovascular invasion, perineural invasion, lymph node
status, and AJCC 8th edition T-staging system were
included as independent variables in the logistic regression
model. For matching, a caliper width of 0.1 times the
standard deviation of the propensity score was used. The
degrees of covariate imbalance in unmatched and matched
samples were measured using the standardized (mean and
proportion) differences as proposed by Austin et al.25 A
p value \0.05 (two-tailed) was considered statistically
significant. All analyses were performed using STATA
version 12.0 (StataCorp LP, College Station, TX, USA) or
R software for statistical computing, v. 3.0.2 34, with the
additional packages, survival, Hmisc and Matching.
RESULTS
Baseline Characteristics of the Study Group Stratified
by the Intrahepatic Cholangiocarcinoma
Morphological Types
Among 1083 patients who underwent liver resection for
ICC, 911 (84.1%) patients had a MF type ICC, 30 (2.8%)
had an IG type, 54 (5.0%) had a PI type, and 88 (8.1%)
patients had an MF ? PI type ICC. Accordingly, 941
(86.9%) patients were included in the MF/IG group, while
142 (13.1%) were included in the PI/MF ? PI group
(Table 1). While most clinical characteristics were com-
parable in the two groups, patients with MF/IG ICC were
younger than patients with PI/MF ? PI ICC tumors (MF/
IG 59 years vs. PI/MF ? PI 63 years; p = 0.008) and had
a lower ASA score (ASA score[2, MF/IG: 53.5% vs. PI/
MF ? PI: 41.8%; p = 0.008). While preoperative tumor
markers such as CEA and CA19-9 were similar (both
p value [0.10), patients with PI/MF ? PI ICC tumors
(27.9%; n = 24) were more likely to have received
neoadjuvant chemotherapy compared with MF/IG patients
(6.8%; n = 53) [p\ 0.001]. While the overwhelming
majority of patients with PI/MF ? PI tumors underwent a
major hepatectomy (n = 134, 94.4%), only approximately
one-half of patients with MF/IG tumors (n = 512, 54.4%)
had a major resection (p\ 0.001). Lymphadenectomy was
also more often performed among patients with PI/
MF ? PI (72.5%) versus MF/IG (40.7%) tumors
(p\ 0.001).
On final pathology, tumor size and number were com-
parable among patients with PI/MF ? PI versus MF/IG
tumors, as was the incidence of poor/undifferentiated ICC
tumors (Table 1). In contrast, compared with MF/IG
patients, PI/MF ? PI tumors were more likely to be asso-
ciated with major vascular invasion (PI/MF ? PI 26.8%
vs. MF/IG 9.5%), as well as lymphovascular (PI/MF ? PI
46.1% vs. MF/IG 28.8%) and perineural invasion (PI/
MF ? PI 37.7% vs. MF/IG 17.9%) [all p\ 0.001]. In
addition, patients with PI/MF ? PI tumors were more
likely to have undergone a margin positive resection (PI/
MF ? PI 23.4% vs. MF/IG 10.8%; p\ 0.001). PI/
MF ? PI patients also had a higher incidence of harboring
metastatic lymph node disease (PI/MF ? PI 59.2% vs. MF/
IG 34.7%; p\ 0.001).
Using the 8th edition of the AJCC staging system, PI/
MF ? PI patients had more advanced T categories (T2/T3/
T4, PI/MF ? PI 77.5% vs. MF/IG 51.4%; p\ 0.001), as
well as N status (N1, PI/MF ? PI 77.2% vs. MF/IG:58.5%;
p = 0.003). Accordingly, 95.0% of PI/MF ? PI patients
were staged as II/IIIa/IIIb versus 86.0% of MF/IG patients
(p = 0.017).
Univariable and Multivariable Survival Analyses
Within a median follow-up of 1.7 years (IQR
0.91–3.46), 537 (49.6%) patients died; 3- and 5-year
overall survival (OS) was 51.9% (95% confidence interval
[CI] 48.6–55.3) and 39.5% (95% CI 35.7–43.3), respec-
tively. Several variables were associated with OS on
univariable analysis, including tumor markers (CEA and
CA 19–9), type of surgery, margin status, invasion of
adjacent organs, tumor size and number, tumor differenti-
ation, major vascular invasion, lymphovascular invasion,
perineural invasion, nodal status, and AJCC 8th edition
staging (Tables 2, 3). In addition, patients with an MF/IG
ICC had a 5-year OS of 41.8% (95% CI 37.7–45.9), which
was markedly better than the 25.5% (95% CI 17.3–34.4)
among patients with a PI/MF ? PI tumor (p\ 0.001)
[Fig. 1].
On multivariable analysis, tumor size ([5 cm; hazard
ratio [HR] 1.75, 95% CI 1.44–2.13), invasion of adjacent
organs (HR 1.75, 95% CI 1.28–2.38), and metastatic nodal
status (HR 2.42, 95% CI 1.84–3.18) [all p\ 0.001]
remained strongly associated with OS (Table 4). In addi-
tion, positive margin status (HR 1.38, 95% CI 1.06–1.79),
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TABLE 1 Baseline characteristics (n = 1083)
Variables ICC MF/IG PI/MF ? PI p Value
No. of patients 1083 941 142
Sex 0.88
Female 466 (43.1) 404 (42.9) 62 (43.7)
Male 617 (56.9) 537 (57.1) 80 (56.3)
Age, years [median (IQR)] 60 (51–69) 59 (51–68) 63 (56–71) 0.008
ASA score 0.008
1–2 614 (56.7) 548 (58.2) 66 (46.5)
3–4 469 (43.3) 393 (41.8) 76 (53.5)
Underlying liver disease \0.001
Cirrhosis 117 (10.8) 112 (11.9) 5 (3.5)
Chronic HBV infection 204 (18.8) 196 (20.8) 8 (5.6)
Chronic HCV infection 31 (2.9) 21 (2.2) 10 (7.1)
None 731 (67.9) 612 (65.1) 119 (83.8)
Neoadjuvant chemotherapy \0.001
No 783 (91.1) 721 (93.2) 62 (72.1)
Yes 77 (8.9) 53 (6.8) 24 (27.9)
NA 223 167 56
CA19–9, U/mL [median (IQR)] 47 (17–190) 45 (16–174) 94 (26–494) 0.12
CEA, ng/mL [median (IQR)] 2.4 (1.4–4.3) 2.4 (1.4–4.2) 2.6 (1.4–5.5) 0.72
Type of surgery \0.001
Wedge resection 169 (15.6) 169 (18.0) 0 (0)
Minor hepatectomy 268 (24.7) 260 (27.6) 8 (5.6)
Major hepatectomy 646 (59.7) 512 (54.4) 134 (94.4)
Margins \0.001
Negative 945 (87.6) 837 (89.2) 108 (76.6)
Positive 134 (12.4) 101 (10.8) 33 (23.4)
NA 4 3 1
Liver capsule involvement 0.25
No 877 (80.9) 767 (81.5) 110 (77.5)
Yes 206 (19.1) 174 (18.5) 32 (22.5)
Invasion of adjacent organs \0.001
No 1017 (93.9) 901 (95.7) 116 (81.7)
Yes 66 (6.1) 40 (4.3) 26 (18.3)
Tumor size, cm 0.06
B5 434 (40.1) 367 (39.0) 67 (47.2)
[5 649 (59.9) 574 (61.0) 75 (52.8)
Lesion 0.12
Unifocal 890 (82.2) 780 (82.9) 110 (77.5)
Multifocal 193 (17.8) 161 (17.1) 32 (22.5)
Grade 0.22
Well–moderate 845 (83.0) 742 (83.6) 103 (79.2)
Poor–undifferentiated 173 (17.0) 146 (16.4) 27 (20.8)
NA 65 53 12
Major vascular invasion \0.001
Not present 956 (88.3) 852 (90.5) 104 (73.2)
Present 127 (11.7) 89 (9.5) 38 (26.8)
Lymphovascular invasion \0.001
Not present 736 (68.9) 660 (71.2) 76 (53.9)
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multifocal ICC (HR 1.38, 95% CI 1.11–1.72), poor/undif-
ferentiated tumor grade (HR 1.60, 95% CI 1.28–2.01), and
perineural invasion (HR 1.28, 95% CI 1.01–1.62) [all
p\ 0.05] were also associated with a poor prognosis. Of
note, after controlling for these competing risk factors,
morphological subtype remained associated with OS as
patients with a PI/MF ? PI ICC had an approximately 40%
higher hazard of death compared with patients who had
MF/IG ICC (HR 1.42, 95% CI 1.11–1.82) [p = 0.006].
Prognosis of Patients and Morphological Types
Given the baseline differences between the MF/IG and
PI/MF ? PI groups, a propensity score-matching analysis
was then performed to minimize potential confounding.
Patients were matched based on age, ASA score, under-
lying liver disease, neoadjuvant chemotherapy, type of
surgery, margin status, invasion of adjacent organs, tumor
size and number, tumor differentiation, vascular invasion,
lymphovascular invasion, perineural invasion, lymph node
status, and AJCC 8th edition T categories.
After the propensity score matching, 95 patients in the
PI/MF ? PI group and 95 patients in the MF/IG group had
comparable characteristics and were subsequently analyzed
(electronic supplementary Table S1) [all p[ 0.1]. In the
propensity score-matched analysis, individuals with MF/IG
ICC still had a more favorable prognosis compared with
patients who had PI/MF ? PI tumors (5-year OS: MF/IG
35.7%, 95% CI 24.0–47.6 vs. PI/MF ? PI 26.2%, 95% CI
16.4–37.1) [p = 0.03].
TABLE 1 continued
Variables ICC MF/IG PI/MF ? PI p Value
Present 332 (31.1) 267 (28.8) 65 (46.1)
NA 15 14 1
Perineural invasion \0.001
Not present 787 (79.5) 706 (82.1) 81 (62.3)
Present 203 (20.5) 154 (17.9) 49 (37.7)
NA 96 81 12
Lymphadenectomy \0.001
Not performed 597 (55.1) 558 (59.3) 39 (27.5)
Performed 486 (44.9) 383 (40.7) 103 (72.5)
Pathological nodal statusa \0.001
Negative 292 (60.1) 250 (65.3) 42 (40.8)
Positive 194 (39.9) 133 (34.7) 61 (59.2)
AJCC 8th edition N categoriesb 0.003
N0 114 (36.7) 96 (41.5) 18 (22.7)
N1 194 (63.3) 133 (58.5) 61 (77.2)
AJCC 8th edition T categories \0.001
T1a 238 (21.9) 223 (23.7) 15 (10.6)
T1b 252 (23.3) 235 (24.9) 17 (11.9)
T2 363 (33.5) 291 (30.9) 72 (50.7)
T3 164 (15.1) 152 (16.2) 12 (8.5)
T4 66 (6.1) 40 (4.3) 26 (18.3)
AJCC 8th edition stagesb 0.017
Ia 15 (4.9) 15 (6.6) 0 (0)
Ib 21 (6.8) 17 (7.4) 4 (5.0)
II 47 (15.3) 37 (16.2) 10 (12.7)
IIIa 26 (8.4) 23 (10.0) 3 (3.8)
IIIb 199 (64.6) 137 (59.8) 62 (78.5)
Data are expressed as n (%) unless otherwise specified
NA not available, ICC intrahepatic cholangiocarcinoma, MF mass forming, IG intraductal growth, PI periductal infiltrating, IQR interquartile
range, ASA American Society of Anesthesiologists, HBV hepatitis B virus, HCV hepatitis C virus, CA cancer antigen, CEA carcinoembryonic
antigen, AJCC American Joint Committee on Cancer
a Patients who underwent lymphadenectomy (N = 486)
b Patients who had at least six lymph nodes harvested (N = 308)
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TABLE 2 Univariate survival analysis (n = 1083)
Variables N = 1083 [n (%)] 5-year OS (%) 95% CI p Value
Sex
Female 66 (43.1) 37.7 32.7–42.7 0.28
Male 617 (56.9) 41.9 36.1–47.6
Age, years 0.63
B65 675 (62.3) 39.4 34.7–44.0
[65 408 (37.7) 39.5 33.1–45.8
ASA score 0.09
1–2 614 (56.7) 40.9 35.6–46.0
3–4 469 (43.3) 37.4 31.9–42.9
Underlying liver disease \0.001
Cirrhosis 117 (10.8) 112 (11.9%) 5 (3.5%)
Chronic HBV infection 204 (18.8) 196 (20.8%) 8 (5.6%)
Chronic HCV infection 31 (2.9) 21 (2.2%) 10 (7.1%)
None 731 (67.9) 612 (65.1%) 119 (83.8%)
Morphological types \0.001
MF/IG 941 (86.9) 41.8 37.7–45.9
PI/MF ? PI 142 (13.1) 25.5 17.3–34.4
Neoadjuvant chemotherapy 0.69
No 783 (91.1) 44.0 39.3–48.6
Yes 77 (8.9) 42.5 26.8–57.3
CA19-9, U/mL \0.001
B50 400 (51.4) 50.7 44.2–56.9
[50 379 (48.5) 31.5 25.6–37.5
CEA, ng/mL \0.001
B10 592 (89.9) 42.9 37.5–48.2
[10 66 (10.1) 4.2 0.4–16.4
Type of surgery 0.011
Wedge resection 169 (15.6) 40.2 29.4–50.7
Minor hepatectomy 268 (24.7) 49.1 40.8–56.8
Major hepatectomy 646 (59.7) 37.8 32.8–42.8
Margins \0.001
Negative 945 (87.6) 40.9 36.9–44.9
Positive 134 (12.4) 29.6 20.1–39.6
Liver capsule involvement
No 877 (80.9) 39.7 35.4–43.9
Yes 206 (19.1) 38.5 30.7–46.3 0.47
Invasion of adjacent organs \0.001
No 1017 (93.9) 43.3 39.1–47.5
Yes 66 (6.1) 14.7 6.4–26.5
Tumor size, cm \0.001
B5 434 (40.1) 51.9 45.9–57.7
[5 649 (59.9) 30.7 26.1–35.5
Lesion \0.001
Unifocal 890 (82.2) 43.3 39.0–47.5
Multifocal 193 (17.8) 22.9 16.0–30.6
Grade \0.001
Well–moderate 845 (83.0) 42.9 38.6–47.2
Poor–undifferentiated 173 (17.0) 22.3 14.9–30.7
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American Joint Committee on Cancer 8th edition T
categories and Morphological Types
Patients were then stratified according to the AJCC 8th
edition T categories, as well as morphologic subtypes
(Tables 5, 6). A total of 749 (69.2%) patients were in the
MF/IG group and in T1a–T1b–T2 stages compared with
only 104 (9.6%) patients in the PI/MF ? PI group and T1a–
T1b–T2 stages. Furthermore, 192 (17.7%) patients were in
the MF/IG group and in T3–T4 stages, while 38 (3.5%)
patients were in the PI/MF ? PI group and in T3–T4 stages.
Of note, even among the T1a–T1b–T2 categories, patients
with MF/IG morphology had a better 5-year OS of 41.6%
(95% CI 36.9–46.3) versus 32.0% (95% CI 21.6–42.9) for
patients with a PI/MF ? PI ICC (p\ 0.001). Similarly,
among patients categorized as T3–T4, 5-year OS following
resection of an MF/IG ICC tumor was 42.5% (95% CI
34.1–50.7) compared with only 5.6% (95% CI 0.5–20.6;
p\ 0.001) for PI/MF ? PI ICC tumors (Fig. 2). Moreover,
compared with T1a–T1b–T2 MF/IG tumors, T1a–T1b–T2
PI/MF ? PI (HR 1.47, 95% CI 1.11–1.94) and T3–T4 PI/
MF ? PI (HR 3.59, 95% CI 2.46–5.23) lesions were asso-
ciated with an increased risk of death. In contrast, patients
with a T3-T4 MF/IG tumor had a comparable risk of death
TABLE 2 continued
Variables N = 1083 [n (%)] 5-year OS (%) 95% CI p Value
Major vascular invasion \0.001
Not present 956 (88.3) 41.6 37.5–45.6
Present 127 (11.7) 26.4 17.4–36.2
Lymphovascular invasion 0.004
Not present 736 (68.9) 43.0 38.5–47.4
Present 332 (31.1) 31.6 26.7–38.7
Perineural invasion 0.001
Not present 787 (79.5) 42.7 38.4–46.9
Present 203 (20.5) 22.1 13.7–31.8
Lymphadenectomy 0.07
Not performed 597 (55.1) 43.9 38.9–48.8
Performed 486 (44.9) 33.4 27.7–39.1
Pathological nodal statusa \0.001
Negative 292 (60.1) 44.3 36.6–51.7
Positive 194 (39.9) 15.7 8.9–24.1
AJCC 8th edition N categories
N0 114 (36.7) 54.5 40.9–66.2 \0.001
N1 194 (63.3) 15.6 8.9–23.9
AJCC 8th edition T categories \0.001
T1a 238 (21.9) 60.9 52.7–68.2
T1b 252 (23.3) 33.9 26.0–41.8
T2 363 (33.5) 29.9 23.6–36.5
T3 164 (15.1) 45.8 36.6–54.6
T4 66 (6.1) 14.7 6.4–26.5
AJCC 8th edition stagesb \0.001
Ia 15 (4.9) 90.9 50.8–98.7
Ib 21 (6.8) 51.9 23.4–74.3
II 47 (15.3) 48.0 27.7–65.7
IIIa 26 (8.4) 42.5 13.4–69.4
IIIb 199 (64.6) 16.6 9.8–25.1
NA not available, OS overall survival, CI confidence interval, MF mass forming, IG intraductal growth, PI periductal infiltrating, ASA American
Society of Anesthesiologists, HBV hepatitis B virus, HCV hepatitis C virus, CA cancer antigen, CEA carcinoembryonic antigen, AJCC American
Joint Committee on Cancer
a Patients who underwent lymphadenectomy (N = 486)
b Patients who had at least six lymph nodes harvested (N = 308)
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versus patients who had a T1a–T1b–T2 MF/IG lesion (HR
1.01, 95% CI 0.79–1.28) [p = 0.95].
DISCUSSION
Similar to other solid malignancies, there has been sig-
nificant interest in identifying clinicopathological factors
associated with survival among patients undergoing cura-
tive-intent surgery for ICC. To this end, several groups
have proposed various staging and prognostic schemes to
stratify ICC patients with regard to prognosis.2,26 For
example, Hyder et al. reported a nomogram that included
six factors, including age, tumor size, number of lesions,
nodal status, vascular invasion, and the presence of cir-
rhosis.26 While the nomogram performed reasonably well,
the overall accuracy was only moderate, with a C-statistic
of 0.706. Such data suggest that other factors may be
important in stratifying patient prognosis following resec-
tion of ICC. One such possible factor may be tumor
morphology, which was first classified by the Liver Cancer
Study of Japan.20 To date, most studies on ICC have failed
to consider, or even report, the morphologic subtype of
ICC tumors included in the analytic cohort.2,7,9,12–17 The
current study is important because we were able to examine
the impact of morphologic ICC subtype in a large, multi-
center cohort of over 1000 patients undergoing surgery for
ICC at one of 14 major hepatobiliary centers in the US,
Europe, Australia, and Asia. Specifically, we noted that
patients with an MF/IG ICC had a much more favorable
prognosis compared with patients who had PI/MF ? PI
tumors. In particular, PI/MF ? PI tumors were associated
with many more aggressive features than MF/IG lesions.
Interestingly, even after controlling for these competing
risk factors, morphologic subtype remained associated with
long-term survival. Moreover, when patients were stratified
by the AJCC 8th edition staging, ICC tumor morphology
was still associated with prognosis within T-category
subgroups (Tables 5, 6).
Similar to previous reports, clinical variables associated
with survival included lymph node status, tumor size and
number, positive margin status, tumor grade, and lym-
phovascular and perineural invasion.6,27 More importantly,
ICC morphologic type was also strongly associated with
OS. Specifically, patients with an MF/IG ICC had a 5-year
OS of 41.8% versus 25.5% for patients with a PI/MF ? PI
tumor (p\ 0.001). Of note, after propensity score match-
ing to control for potential confounding, MF/IG patients
still were noted to have a better OS compared with patients
who had PI/MF ?PI tumors (35.7% vs. 26.2%, respec-
tively). These data were consistent with Shimada et al.,
who reported that patients with MF ICC tumors had a more
favorable prognosis versus the MF ? PI subtype.21 Fur-
thermore, in a separate small study on 52 patients
undergoing curative-intent surgery for ICC, Guglielmi
et al. reported that patients with MF tumors (50 months)
had a markedly longer median survival compared with
either the MF/PI subtype (19 months) or the pure PI sub-
type (15 months).28 In addition, in the current study, the
MF ? PI ICC subtype was associated with more aggres-
sive tumor characteristics, which was consistent with the
study by Shimada et al., which reported MF ? PI ICC
TABLE 3 Comparison between morphological types—Kaplan–Meier analysis
N = 1083 [n (%)] 5-year OS (%) 95% CI p Value
Morphological types \0.001
MF/IG 941 (86.9) 41.8 37.7–45.9
PI/MF ? PI 142 (13.1) 25.5 17.3–34.4
Morphological types—after PSa N = 190 0.034
MF/IG 95 (50.0) 35.7 24.0–47.6
PI/MF ? PI 95 (50.0) 26.2 16.4–37.1
OS overall survival, CI confidence interval, MF mass forming, IG intraductal growth, PI periductal infiltrating


























FIG. 1 Kaplan–Meier overall survival curves stratified by morpho-
logical type classification. MF mass forming, IG intraductal growth,
PI periductal infiltrating
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macroscopic tumor types to be associated with increased
risk of jaundice, bile duct invasion, portal vein invasion,
lymph node metastasis, and R1 margins.21
To further evaluate the prognostic effect of gross tumor
morphology, prognosis was stratified by AJCC 8th edition
T categories by morphological subtype. Among T1a–T1b–
T2 patients (i.e. solitary tumor measuring B 5 cm [T1a];
solitary tumor[5cm [T1b]; solitary tumor with intrahep-
atic vascular invasion or multiple tumors, with or without
vascular invasion [T2]), patients with MF/IG ICC had a
5-year OS of 41.6 versus 32.0% for patients with PI/
MF ? PI tumors (p\ 0.001). A similar difference in sur-
vival based on ICC morphologic subtype was noted among
patients with T3–T4 tumors. Interestingly, T3–T4 MF/IG
patients had a similar risk of death as patients with T1a–
T1b–T2 MF/IG tumors (p = 0.95). Similarly, in a recent
paper from our group comparing the AJCC 7th versus 8th
edition staging systems for ICC, 8th edition T3 patients
paradoxically had a better 5-year OS than either T1 or T2
patients.29 These data, in conjunction with data from the
current study, suggest that factors other than those cur-
rently included in the AJCC staging manual are needed to
improve prognostication of survival among patients with
ICC.
TABLE 4 Multivariable survival analysis—Cox’s model
Variables HR 95% CI p Value
















Not present – –
Present 1.28 1.01–1.62
Pathological nodal statusa \0.001
Negative – –
Positive 2.42 1.84–3.18
Not harvested 1.59 1.27–2.02
Morphological types 0.006
MF/IG – –
PI/MF ? PI 1.42 1.11–1.82
HR hazard ratio, CI confidence interval, MF mass forming, IG intraductal growth, PI periductal infiltrating







































T1a-T1b-T2 MF/IG T1a-T1b-T2 PI/MF+PI
T3-T4 MF/IG T3-T4 PI/MF+PI
FIG. 2 Kaplan–Meier overall survival curves stratified by the AJCC
8th edition T-category staging and morphological type classification.
AJCC American Joint Committee on Cancer, MF mass forming, IG
intraductal growth, PI periductal infiltrating
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The current paper had several limitations that should be
considered. The retrospective nature of the study may have
resulted in selection bias; however, such confounding was
unlikely to impact the evaluation of the prognostic effect of
the morphological status. The multi-institutional nature of
the study likely also caused some heterogeneity in ICC
treatment approach. Finally, the pathological evaluation of
ICC was conducted separately in each center, resulting in
some heterogeneity in the interpretation of the pathological
ICC characteristics. However, including multiple tertiary
referral hepato-pancreatico-biliary (HPB) centers allowed
for a large sample size and a more ‘real-world’ cohort.
CONCLUSION
Among patients undergoing curative-intent resection of
ICC, morphologic subtype was associated with long-term
outcome. In particular, patients with PI or MF ? PI ICC
had an approximately 45% increased risk of death com-
pared with patients who had an MF or IG ICC.
Interestingly, T3–T4 MF/IG patients had a similar risk of
death as T1a–T1b–T2 MF/IG patients. Collectively, these
data suggest that further refinements of staging, such as
including tumor morphology, may be needed to better
define the prognosis of patients with ICC.
DISCLOSURE The authors have no personal conflicts of interest
to declare.
REFERENCES
1. Liver Cancer Study Group of Japan. Intrahepatic cholangiocar-
cinoma macroscopic typing. In: Okamoto E (ed). Classification of
primary liver cancer. Tokyo, Japan, Kanehara; 1997. pp 6–7.
2. Dodson RM, Weiss MJ, Cosgrove D, et al. Intrahepatic cholan-
giocarcinoma: management options and emerging therapies.
TABLE 5 Multivariable survival analysis—Cox’s model with AJCC 8th edition T categories
Variables HR 95% CI p Value
AJCC 8th edition T categories
T1a – – –
T1b 2.01 1.49–2.70 \0.001
T2 2.27 1.71–3.00 \0.001
T3 1.60 1.15–2.23 0.005
T4 3.94 2.71–5.75 \0.001
Morphological types 0.003
MF/IG – –
PI/MF ? PI 1.45 1.14–1.84
AJCC American Joint Committee on Cancer, HR hazard ratio, CI confidence interval, MF mass forming, IG intraductal growth, PI periductal
infiltrating
TABLE 6 AJCC 8th edition and morphological type
N = 1083 [n (%)] 5-year OS (%) 95% CI p Value
AJCC 8th edition T categories \0.001
T1a–T1b–T2 and MF/IG 749 (69.2) 41.6 36.9–46.3
T1a–T1b-T2 and PI/MF ? PI 104 (9.6) 32.0 21.6–42.9
T3–T4 and MF/IG 192 (17.7) 42.5 34.1–50.7
T3–T4 and PI/MF ? PI 38 (3.5) 5.6 0.5–20.6
N = 1083 [n (%)] HR 95% CI p Value
AJCC 8th edition T categories
T1a–T1b–T2 and MF/IG 749 (69.2) – – –
T1a–T1b–T2 and PI/MF ? PI 104 (9.6) 1.47 1.11–1.94 0.007
T3–T4 and MF/IG 192 (17.7) 1.01 0.79–1.28 0.95
T3–T4 and PI/MF ? PI 38 (3.5) 3.59 2.46–5.23 \0.001
AJCC American Joint Committee on Cancer, OS overall survival, HR hazard ratio, CI confidence interval, MF mass forming, IG intraductal
growth, PI periductal infiltrating
2500 F. Bagante et al.
Journal of the American College of Surgeons. 2013;217(4):
736–50.
3. Amini N, Ejaz A, Spolverato G, Kim Y, Herman JM, Pawlik TM.
Temporal trends in liver-directed therapy of patients with intra-
hepatic cholangiocarcinoma in the United States: a population-
based analysis. Journal of Surgical Oncology. 2014;110(2):
163–70.
4. de Jong MC, Nathan H, Sotiropoulos GC, et al. Intrahepatic
cholangiocarcinoma: an international multi-institutional analysis
of prognostic factors and lymph node assessment. Journal of
Clinical Oncology. 2011;29(23):3140–45.
5. Hyder O, Hatzaras I, Sotiropoulos GC, et al. Recurrence after
operative management of intrahepatic cholangiocarcinoma. Sur-
gery. 2013;153(6):811–18.
6. Mavros MN, Economopoulos KP, Alexiou VG, Pawlik TM.
Treatment and prognosis for patients with intrahepatic cholan-
giocarcinoma: systematic review and meta-analysis. JAMA
Surgery. 2014;149(6):565–74.
7. Nathan H, Aloia TA, Vauthey JN, et al. A proposed staging
system for intrahepatic cholangiocarcinoma. Annals of Surgical
Oncology. 2009;16(1):14–22.
8. Nathan H, Pawlik TM. Staging of intrahepatic cholangiocarci-
noma. Current Opinion in Gastroenterology. 2010;26(3):269–73.
9. Spolverato G, Ejaz A, Kim Y, et al. Tumor size predicts
vascular invasion and histologic grade among patients undergo-
ing resection of intrahepatic cholangiocarcinoma. Journal of
Gastrointestinal Surgery. 2014;18(7):1284–91.
10. Spolverato G, Kim Y, Ejaz A, et al. Conditional probability of
long-term survival after liver resection for intrahepatic cholan-
giocarcinoma: a multi-institutional analysis of 535 patients.
JAMA Surgery. 2015;150(6):538–45.
11. Spolverato G, Vitale A, Cucchetti A, et al. Can hepatic resection
provide a long-term cure for patients with intrahepatic cholan-
giocarcinoma? Cancer. 2015;121(22):3998–4006.
12. de Jong MC, Pulitano C, Ribero D, et al. Rates and patterns of
recurrence following curative intent surgery for colorectal liver
metastasis: an international multi-institutional analysis of 1669
patients. Annals of Surgery. 2009;250(3):44–48.
13. Spolverato G, Yakoob MY, Kim Y, et al. The impact of surgical
margin status on long-term outcome after resection for intra-
hepatic cholangiocarcinoma. Annals of Surgical Oncology.
2015;22(12):4020–28.
14. Spolverato G, Kim Y, Alexandrescu S, et al. Is hepatic resection
for large or multifocal intrahepatic cholangiocarcinoma justified?
Results from a multi-institutional collaboration. Annals of Sur-
gical Oncology. 2015;22(7):2218–25.
15. DeOliveira ML, Cunningham SC, Cameron JL, et al. Cholan-
giocarcinoma: thirty-one-year experience with 564 patients at a
single institution. Annals of Surgery. 2007;245(5):755–62.
16. Endo I, Gonen M, Yopp AC, et al. Intrahepatic cholangiocarci-
noma: rising frequency, improved survival, and determinants of
outcome after resection. Annals of Surgery. 2008;248(1):84–96.
17. Nakagohri T, Kinoshita T, Konishi M, Takahashi S, Gotohda N.
Surgical outcome and prognostic factors in intrahepatic cholan-
giocarcinoma. World Journal of Surgery. 2008;32(12):2675–80.
18. Bagante F, Gani F, Spolverato G, et al. Intrahepatic cholangio-
carcinoma: prognosis of patients who did not undergo
lymphadenectomy. Journal of the American College of Surgeons.
2015;221(6):1031–40.
19. Hatzaras I, Schmidt C, Muscarella P, Melvin WS, Ellison EC,
Bloomston M. Elevated CA 19–9 portends poor prognosis in
patients undergoing resection of biliary malignancies. HPB
(Oxford). 2010;12(2):134–38.
20. Yamasaki S. Intrahepatic cholangiocarcinoma: macroscopic type
and stage classification. Journal of Hepato-Biliary-Pancreatic
Surgery. 2003;10(4):288–91.
21. Shimada K, Sano T, Sakamoto Y, Esaki M, Kosuge T, Ojima H.
Surgical outcomes of the mass-forming plus periductal infiltrating
types of intrahepatic cholangiocarcinoma: a comparative study
with the typical mass-forming type of intrahepatic cholangio-
carcinoma. World Journal of Surgery. 2007;31(10):2016–22.
22. Ohtsuka M, Ito H, Kimura F, et al. Results of surgical treatment
for intrahepatic cholangiocarcinoma and clinicopathological
factors influencing survival. The British Journal of Surgery.
2002;89(12):1525–31.
23. Yamamoto M, Takasaki K, Yoshikawa T, Ueno K, Nakano M.
Does gross appearance indicate prognosis in intrahepatic
cholangiocarcinoma? Journal of Surgical Oncology. 1998;69(3):
162–67.
24. Amin MB EiC, American Joint Committee on Cancer. Springer,
New York; 2017.
25. Austin PC, Grootendorst P, Anderson GM. A comparison of the
ability of different propensity score models to balance measured
variables between treated and untreated subjects: a Monte Carlo
study. Statistics in Medicine. 2007;26(4):734–53.
26. Hyder O, Marques H, Pulitano C, et al. A nomogram to predict
long-term survival after resection for intrahepatic cholangiocar-
cinoma: an Eastern and Western experience. JAMA Surgery.
2014;149(5):432–38.
27. Guglielmi A, Ruzzenente A, Campagnaro T, et al. Patterns and
prognostic significance of lymph node dissection for surgical
treatment of perihilar and intrahepatic cholangiocarcinoma.
Journal of Gastrointestinal Surgery. 2013;17(11):1917–28.
28. Guglielmi A, Ruzzenente A, Campagnaro T, et al. Intrahepatic
cholangiocarcinoma: prognostic factors after surgical resec-
tion. World Journal of Surgery. 2009;33(6):1247–54.
29. Spolverato G, Bagante F, Weiss, M, Alexandrescu S, Marques
HP, Aldrighetti L, et al. Comparative performances of the 7th and
the 8th editions of the American Joint Committee on Cancer
staging systems for intrahepatic cholangiocarcinoma. Journal of
Surgical Oncology.
Impact of Morphological Status on Long-Term Outcome Among Patients 2501
